PharmaEssentia Corporation
6446
Pozycja w akcjach
#1439
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Cena akcji
$36.89
Kapitalizacja rynkowa
$15.25B
Zmiana (1 dzień)
-1.28%
Zmiana (1 rok)
144.12%
Kraj
TW
Handel PharmaEssentia Corporation (6446)
Kategoria
Healthcare
Wskaźnik P/B dla PharmaEssentia Corporation (6446)
Wskaźnik P/B na dzień October 2026 TTM: 13.50
Według najnowszych raportów finansowych i ceny akcji PharmaEssentia Corporation, obecny wskaźnik P/B (TTM) wynosi 13.50. Na koniec 2023 wynosił 4.70.
Historia wskaźnika P/B dla PharmaEssentia Corporation od 2010 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 13.50 | 85.23% |
| 2024 | 7.29 | 54.92% |
| 2023 | 4.70 | -57.85% |
| 2022 | 11.16 | -36.95% |
| 2021 | 17.70 | 205.50% |
| 2020 | 5.79 | -44.22% |
| 2019 | 10.39 | -30.22% |
| 2018 | 14.88 | 65.96% |
| 2017 | 8.97 | 16.17% |
| 2016 | 7.72 | -85.09% |
| 2015 | 51.79 | 198.70% |
| 2014 | 17.34 | 0.82% |
| 2013 | 17.20 | -64.44% |
| 2012 | 48.36 | -92.11% |
| 2011 | 613.14 | 490.71% |
| 2010 | 103.80 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -62.67% |
IN
|
